Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

被引:66
作者
Zebaze, Roger [1 ]
Libanati, Cesar [2 ,7 ]
McClung, Michael R. [3 ]
Zanchetta, Jose R. [4 ]
Kendler, David L. [5 ]
Hoiseth, Arne [6 ]
Wang, Andrea [2 ]
Ghasem-Zadeh, Ali [1 ]
Seeman, Ego [1 ]
机构
[1] Univ Melbourne, Austin Hlth, Melbourne, Vic, Australia
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Oregon Osteoporosis Ctr, Portland, OR USA
[4] Inst Invest Metab, Buenos Aires, DF, Argentina
[5] Univ British Columbia, Vancouver, BC, Canada
[6] Curato Rontgen, Oslo, Norway
[7] UCB Pharma, Brussels, Belgium
关键词
DISEASES OF THE BONE-OSTEOPOROSIS; ANALYSIS/QUANTIFICATION OF BONE-OTHER; PRACTICE-FRACTURE PREVENTION; THERAPEUTICS-OTHER; OVARIECTOMIZED CYNOMOLGUS MONKEYS; BONE TURNOVER MARKERS; HUMAN RANKL ANTIBODY; COMPACT-BONE; STRENGTH; FRACTURES; DENSITY; FEMUR; IMPROVEMENTS; COMPARTMENTS;
D O I
10.1002/jbmr.2855
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Hip fractures account for over one-half the morbidity, mortality, and cost associated with osteoporosis. Fragility of the proximal femur is the result of rapid and unbalanced bone remodeling events that excavate more bone than they deposit, producing a porous, thinned, and fragile cortex. We hypothesized that the slowing of remodeling during treatment with denosumab allows refilling of the many cavities excavated before treatment now opposed by excavation of fewer new resorption cavities. The resulting net effect is a reduction in cortical porosity and an increase in proximal femur strength. Images were acquired at baseline and 36 months using multidetector CT in 28 women receiving denosumab and 22 women receiving placebo in a substudy of FREEDOM, a randomized, double-blind, placebo-controlled trial involving women with postmenopausal osteoporosis. Porosity was quantified using StrAx1.0 software. Strength was estimated using finite element analysis. At baseline, the higher the serum resorption marker, CTx, the greater the porosity of the total cortex ( r = 0.34, p = 0.02), and the higher the porosity, the lower the hip strength ( r = -0.31, p = 0.03). By 36 months, denosumab treatment reduced porosity of the total cortex by 3.6% relative to baseline. Reductions in porosity relative to placebo at 36 months were 5.3% in total cortex, 7.9% in compact-appearing cortex, 5.6% in outer transitional zone, and 1.8% in inner transitional zone ( all p<0.01). The improvement in estimated hip integral strength of 7.9% from baseline ( p<0.0001) was associated with the reduction in total porosity ( r = -0.41, p = 0.03). In summary, denosumab reduced cortical porosity of the proximal femoral shaft, resulting in increased mineralized matrix volume and improved strength, changes that may contribute to the reduction in hip and nonvertebral fractures reported with denosumab therapy. (C) 2016 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research ( ASBMR).
引用
收藏
页码:1827 / 1834
页数:8
相关论文
共 33 条
[1]
Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures [J].
Ahmed, L. A. ;
Shigdel, R. ;
Joakimsen, R. M. ;
Eldevik, O. P. ;
Eriksen, E. F. ;
Ghasem-Zadeh, A. ;
Bala, Y. ;
Zebaze, R. ;
Seeman, E. ;
Bjornerem, A. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (08) :2137-2146
[2]
Aging of microstructural compartments in human compact bone [J].
Akkus, O ;
Polyakova-Akkus, A ;
Adar, F ;
Schaffler, MB .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1012-1019
[3]
[Anonymous], 2004, US Health and Human Services, P437
[4]
Baron R., 1977, Toulouse, P179
[5]
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J].
Burge, Russel ;
Dawson-Hughes, Bess ;
Solomon, Daniel H. ;
Wong, John B. ;
King, Alison ;
Tosteson, Anna .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (03) :465-475
[6]
A Longitudinal HR-pQCT Study of Alendronate Treatment in Postmenopausal Women With Low Bone Density: Relations Among Density, Cortical and Trabecular Microarchitecture, Biomechanics, and Bone Turnover [J].
Burghardt, Andrew J. ;
Kazakia, Galateia J. ;
Sode, Miki ;
de Papp, Anne E. ;
Link, Thomas M. ;
Majumdar, Sharmila .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (12) :2282-2295
[7]
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765
[8]
FROST HM, 1985, BONE MINERAL RES, V3, P49
[9]
Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab [J].
Genant, Harry K. ;
Libanati, Cesar ;
Engelke, Klaus ;
Zanchetta, Jose R. ;
Hoiseth, Arne ;
Yuen, Chui Kin ;
Stonkus, Sigtas ;
Bolognese, Michael A. ;
Franek, Edward ;
Fuerst, Thomas ;
Radcliffe, Hoi-Shen ;
McClung, Michael R. .
BONE, 2013, 56 (02) :482-488
[10]
SUGGESTED SEQUENTIAL MODE OF CONTROL OF CHANGES IN CELL BEHAVIOUR IN ADULT BONE REMODELLING [J].
HATTNER, R ;
EPKER, BN ;
FROST, HM .
NATURE, 1965, 206 (4983) :489-+